First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial

Author:

Wu Xiaohua1ORCID,Liu Jihong2ORCID,An Ruifang3ORCID,Yin Rutie4ORCID,Zhang Yu5ORCID,Zhou Huaijun6ORCID,He Aiqin7ORCID,Wang Li8ORCID,Zhang Jieqing9ORCID,Liu Ziling10ORCID,Duan Wei11ORCID,Zhu Jianqing12ORCID,Lou Ge13ORCID,Chen Guilin14ORCID,Cheng Ying15ORCID,Xue Fengxia16ORCID,Nick Sonja17ORCID,Wang Haiyan18ORCID,Li Donghang18ORCID

Affiliation:

1. Fudan University Shanghai Cancer Center, Shanghai, China.

2. Sun Yat-sen University Cancer Center, Guangzhou, China.

3. First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China.

4. Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.

5. Xiangya Hospital Central South University, Changsha, China.

6. Nanjing Drum Tower Hospital, Nanjing, China.

7. Nantong Tumor Hospital, Nantong, China.

8. Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

9. Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College, Nanning, China.

10. The First Hospital of Jilin University, Changchun, China.

11. Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.

12. Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

13. Harbin Medical University Cancer Hospital, Harbin, China.

14. Fujian Cancer Hospital, Fuzhou, China.

15. Jilin Cancer Hospital, Changchun, China.

16. Tianjin Medical University General Hospital, Tianjin, China.

17. F. Hoffmann-La Roche Ltd, Basel, Switzerland.

18. Roche Product Development, Shanghai, China.

Funder

F. Hoffmann-La Roche

Publisher

XMLink

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3